Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.

Whether millions gain access to breakthrough anti-obesity treatments may depend on Kennedy, Mehmet Oz and other key players ...

Few companies garner as much reliable attention as Novo Nordisk ( NVO) does these days. With a bull market coinciding with a ...

But basically it’s all about hitting the brain’s satiety centres. The new drugs make you feel full much more quickly and ...

But for a long time China’s people struggled to get hold of Wegovy because the country’s regulators had not approved it. Some ...

The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday, Nov. 26, announced proposed changes in Medicare and Medicaid that would formally recognize obesity as a disease, meaning ...

Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...

Millions of Americans would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic covered by Medicare ...

NEW YORK (Reuters) - The U.S. pharmaceutical industry is pushing to revamp the new law that allows Medicare to negotiate prices for its costliest prescription drugs once president-elect Donald Trump ...

My sister, who is a lifelong Democrat, wanted to school me on everything from the "real" causes of inflation - the pandemic, ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

Share on Facebook Share on Twitter Under a new rule the Biden administration proposed on Tuesday, millions of Americans with ...